YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
On August 3, ORIC Pharmaceuticals (NASDAQ:ORIC) reported second-quarter results that showed a clinical-stage biotech converting years of early work into two separate late-stage bets at once. The company started Himalayas-1, a global Phase…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, to…
(RTTNews) - ORIC Pharmaceuticals, Inc. (ORIC), a clinical-stage oncology company, reported a wider net loss for the second quarter ended June 30, 2026, and provided updates on its clinical pipeline. Company Profile ORIC Pharmaceuticals is…
* ORIC Pharmaceuticals press release [https://seekingalpha.com/pr/20604753-oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-updates] (ORIC [https://seekingalpha.com/symbol/ORIC]): Q2 GAAP EPS of -$0.38 mis…
ORIC Pharmaceuticals Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1…
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients wi…
ORIC Pharmaceuticals Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, to…
(RTTNews) - Biotech stocks are showing strong pre-market moves this Tuesday, hinting at possible breakout setups. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket Gainers On Tuesd…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, to…
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newact…
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newa…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, t…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.48%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.18%. June E-mini S&P futures (ESM26) rose +0.74%, and June E…
The S&P 500 Index ($SPX) (SPY) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.48%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.18%. June E-mini S&P futures (ESM26) rose +0.74%, and June E…
Shares of Oric Pharmaceuticals sank 40% Wednesday after the cancer biotech reported study results that were positive--but not positive enough for Wall Street. In an early-stage trial, Oric’s prostate-cancer drug candidate showed signs of a…
The S&P 500 Index ($SPX) (SPY) today is up +0.97%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.86%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.45%. June E-mini S&P futures (ESM26) are up +0.96%, and June E-mini Nasdaq futu…
The S&P 500 Index ($SPX) (SPY) today is up +0.52%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.43%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.68%. June E-mini S&P futures (ESM26) are up +0.57%, and June E-mini Nasdaq futu…
(RTTNews) - Oric Pharmaceuticals (ORIC), a clinical-stage biopharmaceutical company, reported new dose-optimisation results for its Rinzimetostat or ORIC-944 from the Phase Ib Study, and outlined plans to begin its first phase III registra…
The S&P 500 Index ($SPX) (SPY) today is up +0.97%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.86%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.45%. June E-mini S&P futures (ESM26) are up +0.96%, and June E-mini Nasdaq futu…
The S&P 500 Index ($SPX) (SPY) today is up +0.52%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.43%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.68%. June E-mini S&P futures (ESM26) are up +0.57%, and June E-mini Nasdaq futu…
Oric stock crashed Wednesday after the company indicated its prostate cancer treatment is roughly as effective as a competitor. Continue Reading
US stocks looked set to open higher in Wednesday's trading session after President Trump claimed tha PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Nextech Invest, Ltd. disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it reduced its stake in Kymera Therapeutics(NASDAQ:KYMR) by 62,013 shares, an estimated $4.19 million trade based on quarterly aver…
In recent days, Oric Pharmaceuticals has come under pressure after Ipsen voluntarily withdrew its EZH2 inhibitor Tazverik from the market due to secondary hematologic malignancy concerns in a confirmatory study, prompting questions about s…
Quick Read Jefferies initiated on Gilead (GILD) with a $180 target (trades at $146.63, up 19.46% YTD) and Amgen (AMGN) at $350 (trades at $376.97, up 15.96% YTD). JPMorgan maintained Oric (ORIC) at $11.65, down 16.07% past week. Jefferies…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, t…
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $25 from $23 and keeps a Buy rating on the shares. The firm, which is pulling its valuation forward, says it expects the next 12 months t…
(RTTNews) - ORIC Pharmaceuticals, Inc. (ORIC), a clinical-stage oncology company, on Monday reported a narrower loss for the fourth quarter. Net loss for the fourth quarter shrank to $30.51 million or $0.30 loss per share from $36.31 milli…
* ORIC Pharmaceuticals press release [https://seekingalpha.com/pr/20409735-oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and] (ORIC [https://seekingalpha.com/symbol/ORIC]): Q4 GAAP EPS of -$0.30 beats by…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, to…
Cancer remains one of the world’s deadliest challenges. Second only to heart disease, it claims one in every six lives globally – about 10 million deaths each year – and the numbers are still climbing as lifestyle factors such as smoking,…
ORIC Pharmaceuticals recently drew investor attention with positive analyst commentary, new clinical data on its lead oncology candidates, and a high-profile presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisc…
Oric Pharmaceuticals stock cleared that benchmark Thursday, with a jump from 61 to 80 Thursday. IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over…
* ORIC Pharmaceuticals (ORIC [https://seekingalpha.com/symbol/ORIC]) on Monday announced operational highlights for 2025 and anticipated upcoming milestones. * ORIC anticipates the following upcoming milestones: * Rinzimetostat in mCRPC: *…
ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of ther…